Medinotec Inc. (MDNC) intrinsic value & 10-year financials
Medinotec Inc. (MDNC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 113.5% a year to $9.7M, with an average return on invested capital of 163.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.00
- Revenue (FY2026)
- $9.7M
- Revenue growth (6-yr CAGR)
- 113.5%
- ROIC (10-yr avg)
- 163.8%
- Free cash flow (FY2026)
- $905.4K
MDNC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $9.7M | $794.5K | — | $905.4K | 11.2% | 72.3% |
| FY2025 | $9.1M | $2.2M | — | $788.8K | 35.0% | 700.0% |
| FY2024 | $5.0M | -$404.7K | — | $12.0K | 12.0% | -72.7% |
| FY2023 | $999.6K | -$352.7K | — | -$545.8K | -46.6% | -44.6% |
| FY2022 | — | — | — | — | — | — |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Medinotec Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Medinotec Inc. has historically struggled to out-earn its cost of capital, averaging just -9.5% ROIC.
Medinotec Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Medinotec Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.